Key result
Nab-paclitaxel achieved stable disease after 2 cycles and successfully controlled disseminated intravascular coagulation for at least 4 months in a patient with primary cardiac angiosarcoma.
Why the study?
Does nab-paclitaxel improve tumor response and control DIC in a patient with primary cardiac angiosarcoma and coexisting DIC?
Case Report (n=1)
Does nab-paclitaxel improve tumor response and control DIC in a patient with primary cardiac angiosarcoma and coexisting DIC?
Nab-paclitaxel demonstrated potential utility in achieving stable disease and controlling DIC in a patient with primary cardiac angiosarcoma.
Should not yet change practice for cardiac angiosarcoma with DIC; hypothesis-generating and requires prospective validation.
Angiosarcoma of the heart is an uncommon soft tissue sarcoma. A few cases of disseminated intravascular coagulation (DIC) associated with angiosarcoma occurring in various organs, but not the heart, have been reported. Although taxane is commonly used in the treatment of metastatic angiosarcoma, data on the efficacy of nab-paclitaxel for angiosarcoma are limited. Here, we report probably the first case of a patient with primary cardiac angiosarcoma with coexisting DIC who was successfully treated with nab-paclitaxel. A 62-year-old female with chief complaints of nausea and shortness of breath was diagnosed as having cardiac angiosarcoma with liver metastases. Four months after the resection of her primary tumor, the hepatic metastatic lesions progressed rapidly accompanied by new metastatic lesions in the right iliac bone and signs of DIC. She received nab-paclitaxel as first-line chemotherapy. A response of stable disease was achieved after 2 treatment cycles and DIC was successfully controlled for at least 4 months. This report suggests potential utility of nab-paclitaxel for angiosarcoma complicated with DIC. We also review the literature for all cases of angiosarcoma with DIC reported so far.
No takes yet. Share an insight, caveat, or question.
Honda et al. (2017) conducted a case report in Primary cardiac angiosarcoma with coexisting disseminated intravascular coagulation (DIC) (n=1). Nab-paclitaxel was evaluated on Disease response and DIC control. Nab-paclitaxel achieved stable disease after 2 cycles and successfully controlled disseminated intravascular coagulation for at least 4 months in a patient with primary cardiac angiosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: